IRD
Bearish signalScored 2026-10-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Opus Genetics, Inc.
- Nom
- Opus Genetics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $289.7M
- Employés
- 28
- PDG
- George Magrath
- Site web
- https://opusgtx.com
- Marché
- ABOSAGENALECCGTXHURAINO
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 556 000 titres (~2 755 980,80 $ US)
- Insiders
- Foundation Fighting Blindness Retinal Degeneration Fund
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,883,193
Avg sell (VWAP, 90d window) $4.94 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-30
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund | Sell · S | 556,000 | $4.96 | $2,755,981 | Form 4 |
| 2026-09-03 | Gagnon Robert E. | Sell · S | 28,000 | $4.54 | $127,212 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-03 Drivers: fundamentals. Moteurs : fondamentaux.
IRD presents a compelling clinical catalyst with Phase 1/2 OPGx-BEST1 data driving strong price momentum and a 'Moderate Buy' consensus, but this must be weighed against severely deteriorating fundamentals marked by…
The first sentence of the analysis written for IRD on 2026-10-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 6.43 · operating margin -272% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -339.0% | -523.4% | -52.4% | 45.7% | -9625.0% | |
| Ebitda Margin | -338.6% | -523.3% | -52.3% | 45.7% | -9624.3% | |
| Operating Profit Margin | -271.9% | -564.7% | -55.5% | 45.7% | -3854.8% | |
| Pretax Profit Margin | -349.3% | -523.4% | -52.4% | 45.7% | -9625.3% | |
| Continuous Operations Profit Margin | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% | |
| Net Profit Margin | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% | |
| Bottom Line Profit Margin | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% | |
| Current Ratio | 6.432 | 3.241 | 13.347 | 17.794 | 6.762 | |
| Quick Ratio | 6.432 | 3.241 | 13.347 | 17.794 | 6.762 | |
| Solvency Ratio | -1.420 | -1.909 | -2.469 | 6.499 | -14.705 | |
| Cash Ratio | 5.795 | 2.684 | 12.494 | 15.486 | 6.364 | |
| Price To Earnings Ratio | -2.512 | -0.553 | -2.804 | 1.433 | -0.338 | |
| Price To Earnings Growth Ratio | 0.040 | -0.002 | 0.019 | -0.012 | 0.012 | |
| Forward Price To Earnings Growth Ratio | 0.040 | -0.002 | 0.019 | -0.012 | 0.012 | |
| Price To Earnings Diluted Ratio | -2.512 | -0.553 | -2.804 | 1.483 | -0.338 | |
| Price To Earnings Diluted Growth Ratio | 0.040 | -0.002 | 0.018 | -0.012 | 0.012 | |
| Price To Book Ratio | 81.487 | 4.728 | 0.558 | 0.556 | 0.862 | |
| Price To Sales Ratio | 88.099 | 2.892 | 1.462 | 0.645 | 32.530 | |
| Price To Free Cash Flow Ratio | -35.477 | -1.243 | -25.046 | 1.796 | -0.989 | |
| Price To Operating Cash Flow Ratio | -35.477 | -1.243 | -25.046 | 1.796 | -0.989 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.021 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.024 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.024 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.274 | 5.482 | 1.081 | 1.060 | 1.173 | |
| Working Capital Turnover Ratio | 0.420 | 0.292 | 0.396 | 1.164 | 0.032 | |
| Operating Cash Flow Ratio | -4.531 | -2.264 | -0.275 | 5.199 | -5.025 | |
| Operating Cash Flow Sales Ratio | -2.483 | -2.327 | -0.058 | 0.359 | -32.886 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -32.791 | 0.000 | -7.515 | 1,989.000 | -104.976 | |
| Interest Coverage Ratio | -26.329 | 0.000 | -7.954 | 2,025.111 | -11,352.500 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -36.004 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -36.004 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -25.078 | -0.026 | 2.272 | -0.929 | 0.085 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 0.0% |
| Ebit Margin | -339.0% | ▲184.4% | ▲1759.8% |
| Ebitda Margin | -338.6% | ▲184.7% | ▲1759.9% |
| Operating Profit Margin | -271.9% | ▲292.8% | ▲668.3% |
| Pretax Profit Margin | -349.3% | ▲174.1% | ▲1751.6% |
| Continuous Operations Profit Margin | -349.3% | ▲174.1% | ▲1751.8% |
| Net Profit Margin | -349.3% | ▲174.1% | ▲1751.8% |
| Bottom Line Profit Margin | -349.3% | ▲174.1% | ▲1751.8% |
| Current Ratio | 6.432 | ▲3.190 | ▼-3.083 |
| Quick Ratio | 6.432 | ▲3.190 | ▼-3.083 |
| Solvency Ratio | -1.420 | ▲0.489 | ▲1.381 |
| Cash Ratio | 5.795 | ▲3.111 | ▼-2.770 |
| Price To Earnings Ratio | -2.513 | ▼-1.959 | ▼-1.558 |
| Price To Earnings Growth Ratio | 0.040 | ▲0.042 | ▲0.029 |
| Forward Price To Earnings Growth Ratio | 0.040 | ▲0.042 | ▲0.029 |
| Price To Earnings Diluted Ratio | -2.513 | ▼-1.959 | ▼-1.567 |
| Price To Earnings Diluted Growth Ratio | 0.040 | ▲0.042 | ▲0.029 |
| Price To Book Ratio | 81.487 | ▲76.759 | ▲63.849 |
| Price To Sales Ratio | 88.100 | ▲85.207 | ▲62.974 |
| Price To Free Cash Flow Ratio | -35.477 | ▼-34.234 | ▼-23.285 |
| Price To Operating Cash Flow Ratio | -35.477 | ▼-34.234 | ▼-23.285 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.004 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▼-0.005 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.005 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 3.274 | ▼-2.209 | ▲0.860 |
| Working Capital Turnover Ratio | 0.420 | ▲0.128 | ▼-0.041 |
| Operating Cash Flow Ratio | -4.531 | ▼-2.266 | ▼-3.152 |
| Operating Cash Flow Sales Ratio | -2.483 | ▼-0.157 | ▲4.996 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | -32.791 | ▼-32.791 | ▼-401.535 |
| Interest Coverage Ratio | -26.329 | ▼-26.329 | ▲1846.005 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲7.201 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲7.201 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -25.078 | ▼-25.053 | ▼-20.343 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.25B | $31.8M | $27.9M | $25.7M | $19.2M | |
| Enterprise value | $1.21B | $1.5M | -$22.7M | -$16.9M | -$4.8M | |
| EV / Sales | 84.92x | 0.13x | -1.19x | -0.42x | -8.21x | |
| EV / Op. cash flow | -34.20x | -0.06x | 20.37x | -1.18x | 0.25x | |
| EV / Free cash flow | -34.20x | -0.06x | 20.37x | -1.18x | 0.25x | |
| EV / EBITDA | -25.08x | -0.03x | 2.27x | -0.93x | 0.09x | |
| Net debt / EBITDA | 0.94x | 0.53x | 5.07x | -2.34x | 0.42x | |
| Current ratio | 6.43x | 3.24x | 13.35x | 17.79x | 6.76x | |
| Income quality | 0.71x | 0.45x | 0.11x | 0.80x | 0.34x | |
| Graham number | — | — | — | $7 | — | |
| Graham net-net | $0 | $0 | $2 | $2 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.1% | 98.3% | 100.0% | |
| Interest burden | 103.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $42.3M | $25.3M | $49.9M | $46.2M | $22.2M | |
| Invested capital | $42.5M | $25.6M | $49.9M | $46.2M | $22.2M | |
| Return on assets | -98.7% | -156.1% | -18.5% | 36.5% | -217.4% | |
| Operating ROA | -88.6% | -136.7% | -20.5% | 48.6% | -103.8% | |
| Return on tangible assets | -98.7% | -156.1% | -18.5% | 36.5% | -217.4% | |
| Return on equity | -323.1% | -855.6% | -20.0% | 38.7% | -255.1% | |
| Return on invested capital | -90.9% | -242.8% | -21.2% | 38.7% | -99.8% | |
| Return on capital employed | -90.9% | -242.8% | -21.2% | 39.4% | -102.2% | |
| Earnings yield | -4.0% | -181.0% | -35.9% | 69.6% | -295.9% | |
| Free cash flow yield | -2.8% | -80.4% | -4.0% | 55.7% | -101.1% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 154.9% | 165.7% | 62.8% | 18.2% | 1378.8% | |
| R&D / Sales | 217.0% | 244.3% | 92.7% | 36.0% | 2576.1% | |
| Stock comp / Sales | 23.9% | 30.6% | 18.4% | 4.5% | 325.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 81d | 192d | 45d | 44d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 81d | 192d | 45d | 44d | 0d | |
| Cash conversion cycle | 81d | 192d | 45d | 44d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+3833.9%EV / Sales ▲+63381.2%EV / EBITDA ▼-98001.6%EV / Op. cash flow ▼-34.140Earnings yield ▲+1.770
Profitability
Return on equity ▲+5.325Return on assets ▲+0.574Return on invested capital ▲+1.519Return on capital employed ▲+1.519Operating ROA ▲+0.481Income quality ▲+0.266Tax burden 0.000
Efficiency
Days sales outstanding ▼-110.288Days payables outstanding n/aOperating cycle ▼-110.288Cash conversion cycle ▼-110.288Capex / Sales n/aR&D / Sales ▼-0.272
Balance-sheet strength
Current ratio ▲+3.190Net debt / EBITDA ▲+0.411Working capital ▲+16948000.000Invested capital ▲+16895000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+6427.4%EV / Sales ▲+1134.3%EV / EBITDA ▼-29496.9%EV / Op. cash flow ▼-34.447Earnings yield ▲+2.919
Profitability
Return on equity ▼-0.680Return on assets ▲+1.187Return on invested capital ▲+0.089Return on capital employed ▲+0.113Operating ROA ▲+0.151Income quality ▲+0.369Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales ▼-23.590
Balance-sheet strength
Current ratio ▼-0.330Net debt / EBITDA ▲+0.515Working capital ▲+20051000.000Invested capital ▲+20240000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-10-01 Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, fifteen have given a buy recommendation and one has given
- 2026-09-17 Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD Squarepoint Ops LLC purchased a new stake in Opus Genetics, Inc. (NASDAQ: IRD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 330,783 shares of the company''s stock, valued at approximately $1,360,000. Squarepoint Ops LLC owned about 0.40% of Opus
- 2026-09-10 Opus Genetics: A Resounding Study Success Merits A Higher Valuation Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. OPGx-BEST1 showed clinically meaningful visual improvements and strong safety in all Cohort 1 patients, with greater gains in less advanced disease. IRD''s pipeline targets large, underserved markets with no approved therapies; cash runway extends into 2029, supporting ongoing pivotal studies.
- 2026-09-10 Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
- 2026-09-09 Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says Opus Genetics, Inc. (NASDAQ:IRD) stock is surging on Wednesday after the company reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1.
- 2026-09-09 Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual function, with structural improvements observed in four participants FDA aligned on ≥3 decibels microperimetry improvement in conjunction with patient reported outcomes as a potential pivotal endpoint Clinically meaningful best-corrected visual acuity improvements in 3 of 5 participants and retinal sensitivity improvements on microperimetry observed in 3 of 4 evaluable participants Cohort 2 over-enrolled, with dosing expected to be completed in Q4 2026 and topline 3-month data expected in Q2 2027 Cash runway into 2029 expected to support multiple clinical inflection points and opportunities for priority review vouchers Webcast and conference call today at 8:00 a.m. ET with management and Key Opinion Leader and retinal specialist, Mark Pennesi, M.D.
- 2026-09-09 Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $10.69 Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eighteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, fifteen have assigned a buy rating and one
- 2026-09-02 Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings RESEARCH TRIANGLE PARK, N.C.
- 2026-08-26 ADAR1 Capital Management LLC Takes $7.33 Million Position in Opus Genetics, Inc. $IRD ADAR1 Capital Management LLC acquired a new position in Opus Genetics, Inc. (NASDAQ: IRD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,783,781 shares of the company''s stock, valued at approximately $7,331,000. ADAR1 Capital Management LLC owned 2.16% of Opus Genetics
- 2026-08-19 Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company''s 2021 Inducement Plan, as amended, as a material inducement to employment to three non-executive employees who were not previously employees or directors of the Company.